{"id":72632,"date":"2023-09-08T17:37:58","date_gmt":"2023-09-08T12:07:58","guid":{"rendered":"https:\/\/enterslice.com\/learning\/?post_type=hsn-code&#038;p=72632"},"modified":"2023-10-04T15:34:27","modified_gmt":"2023-10-04T10:04:27","slug":"3002","status":"publish","type":"hsn-code","link":"https:\/\/enterslice.com\/learning\/hsn-code\/3002\/","title":{"rendered":"Human Blood Animal Blood &#8211; GST Rates &amp; HSN Code 3002"},"content":{"rendered":"<p>Origin Chapter:&nbsp;<a href=\"https:\/\/enterslice.com\/learning\/hsn-code\/chapter-30-pharmaceutical-products-gst-rate-hsn-code\/\">Chapter 30<\/a><\/p>\n\n\n\n<p>Discover GST rates &amp; HSN code 3002 for Human and Animal Blood products. Ensure tax compliance with our comprehensive guide.<\/p>\n\n\n\n<figure class=\"wp-block-table\"><table><tbody><tr><th>HSN Code<\/th><th>Description<\/th><th>Rate (%)<\/th><th>CESS (%)<\/th><th>Effective Date<\/th><th>Rate Revision<\/th><\/tr><tr><td>3002<\/td><td>Human Blood; Animal Blood Prepared For Therapeutic, Prophylactic Or Diagnostic Uses; Antisera, Other Blood Fractions And Immunological Products, Whether Or Not Modified Or Obtained By Means Of Biotechnological Processes; Vaccines, Toxins, Cultures Of Micr<\/td><td>5\/12<\/td><td>0<\/td><td>13\/10\/2017 1\/07\/2017<\/td><td>5% 12%<\/td><\/tr><tr><td>300210<\/td><td>Antisera, Other Blood Fractions And Immunological Products, Whether Or Not Modified Or Obtained By Biotechnological Processes<\/td><td>5\/12<\/td><td>0<\/td><td>13\/10\/2017 1\/07\/2017<\/td><td>5% 12%<\/td><\/tr><tr><td>30021011<\/td><td>Human Blood; Animal Blood Prepared For Therapeutic, Prophylactic Or Diagnostic Uses; Antisera And Other Blood Fractions And Modified Immunological Products, Whether Or Not Obtained By Means Of Biotechnological Processes; Vaccines, Toxins, Cultures Of Micr<\/td><td>5\/12<\/td><td>0<\/td><td>13\/10\/2017 1\/07\/2017<\/td><td>5% 12%<\/td><\/tr><tr><td>30021012<\/td><td>Human Blood; Animal Blood Prepared For Therapeutic, Prophylactic Or Diagnostic Uses; Antisera And Other Blood Fractions And Modified Immunological Products, Whether Or Not Obtained By Means Of Biotechnological Processes; Vaccines, Toxins, Cultures Of Micr<\/td><td>5\/12<\/td><td>0<\/td><td>13\/10\/2017 1\/07\/2017<\/td><td>5% 12%<\/td><\/tr><tr><td>30021013<\/td><td>Human Blood; Animal Blood Prepared For Therapeutic, Prophylactic Or Diagnostic Uses; Antisera And Other Blood Fractions And Modified Immunological Products, Whether Or Not Obtained By Means Of Biotechnological Processes; Vaccines, Toxins, Cultures Of Micr<\/td><td>5\/12<\/td><td>0<\/td><td>13\/10\/2017 1\/07\/2017<\/td><td>5% 12%<\/td><\/tr><tr><td>30021014<\/td><td>Human Blood; Animal Blood Prepared For Therapeutic, Prophylactic Or Diagnostic Uses; Antisera And Other Blood Fractions And Modified Immunological Products, Whether Or Not Obtained By Means Of Biotechnological Processes; Vaccines, Toxins, Cultures Of Micr<\/td><td>5\/12<\/td><td>0<\/td><td>13\/10\/2017 1\/07\/2017<\/td><td>5% 12%<\/td><\/tr><tr><td>30021019<\/td><td>Human Blood; Animal Blood Prepared For Therapeutic, Prophylactic Or Diagnostic Uses; Antisera And Other Blood Fractions And Modified Immunological Products, Whether Or Not Obtained By Means Of Biotechnological Processes; Vaccines, Toxins, Cultures Of Micr<\/td><td>5\/12<\/td><td>0<\/td><td>13\/10\/2017 1\/07\/2017<\/td><td>5% 12%<\/td><\/tr><tr><td>30021020<\/td><td>Human Blood; Animal Blood Prepared For Therapeutic, Prophylactic Or Diagnostic Uses; Antisera And Other Blood Fractions And Modified Immunological Products, Whether Or Not Obtained By Means Of Biotechnological Processes; Vaccines, Toxins, Cultures Of Micr<\/td><td>5\/12<\/td><td>0<\/td><td>13\/10\/2017 1\/07\/2017<\/td><td>5% 12%<\/td><\/tr><tr><td>30021091<\/td><td>Human Blood; Animal Blood Prepared For Therapeutic, Prophylactic Or Diagnostic Uses; Antisera And Other Blood Fractions And Modified Immunological Products, Whether Or Not Obtained By Means Of Biotechnological Processes; Vaccines, Toxins, Cultures Of Micr<\/td><td>5\/12<\/td><td>0<\/td><td>13\/10\/2017 1\/07\/2017<\/td><td>5% 12%<\/td><\/tr><tr><td>30021099<\/td><td>Human Blood; Animal Blood Prepared For Therapeutic, Prophylactic Or Diagnostic Uses; Antisera And Other Blood Fractions And Modified Immunological Products, Whether Or Not Obtained By Means Of Biotechnological Processes; Vaccines, Toxins, Cultures Of Micr<\/td><td>5\/12<\/td><td>0<\/td><td>13\/10\/2017 1\/07\/2017<\/td><td>5% 12%<\/td><\/tr><tr><td>30021100<\/td><td>Malaria Diagnostic Test Kits<\/td><td>5\/12<\/td><td>0<\/td><td>13\/10\/2017 1\/07\/2017<\/td><td>5% 12%<\/td><\/tr><tr><td>300212<\/td><td>Antisera And Other Blood Fractions<\/td><td>5\/12<\/td><td>0<\/td><td>13\/10\/2017 1\/07\/2017<\/td><td>5% 12%<\/td><\/tr><tr><td>30021210<\/td><td>For Diphtheria<\/td><td>5\/12<\/td><td>0<\/td><td>13\/10\/2017 1\/07\/2017<\/td><td>5% 12%<\/td><\/tr><tr><td>30021220<\/td><td>For Tetanus<\/td><td>5\/12<\/td><td>0<\/td><td>13\/10\/2017 1\/07\/2017<\/td><td>5% 12%<\/td><\/tr><tr><td>30021230<\/td><td>For Rabies<\/td><td>5\/12<\/td><td>0<\/td><td>13\/10\/2017 1\/07\/2017<\/td><td>5% 12%<\/td><\/tr><tr><td>30021240<\/td><td>For Snake Venom<\/td><td>5\/12<\/td><td>0<\/td><td>13\/10\/2017 1\/07\/2017<\/td><td>5% 12%<\/td><\/tr><tr><td>30021290<\/td><td>Other<\/td><td>5\/12<\/td><td>0<\/td><td>13\/10\/2017 1\/07\/2017<\/td><td>5% 12%<\/td><\/tr><tr><td>300213<\/td><td>Immunological Products, Unmixed, Not Put Up In Measured Doses Or In Forms Or Packings For Retail Sale<\/td><td>5\/12<\/td><td>0<\/td><td>13\/10\/2017 1\/07\/2017<\/td><td>5% 12%<\/td><\/tr><tr><td>30021310<\/td><td>Immunological Products, Unmixed, Not Put Up In Measured Doses Or In Forms Or Packings For Retail Sale<\/td><td>5\/12<\/td><td>0<\/td><td>13\/10\/2017 1\/07\/2017<\/td><td>5% 12%<\/td><\/tr><tr><td>300214<\/td><td>Immunological Products, Mixed, Not Put Up In Measured Doses Or In Forms Or Packings For Retail Sale<\/td><td>5\/12<\/td><td>0<\/td><td>13\/10\/2017 1\/07\/2017<\/td><td>5% 12%<\/td><\/tr><tr><td>30021410<\/td><td>Immunological Products, Mixed, Not Put Up In Measured Doses Or In Forms Or Packings For Retail Sale<\/td><td>5\/12<\/td><td>0<\/td><td>13\/10\/2017 1\/07\/2017<\/td><td>5% 12%<\/td><\/tr><tr><td>30021500<\/td><td>Immunological Products, Put Up In Measured Doses Or In Forms Or Packings For Retail Sale<\/td><td>5\/12<\/td><td>0<\/td><td>13\/10\/2017 1\/07\/2017<\/td><td>5% 12%<\/td><\/tr><tr><td>30021900<\/td><td>Other<\/td><td>5\/12<\/td><td>0<\/td><td>13\/10\/2017 1\/07\/2017<\/td><td>5% 12%<\/td><\/tr><tr><td>300220<\/td><td>Vaccines For Human Medicine<\/td><td>5\/12<\/td><td>0<\/td><td>13\/10\/2017 1\/07\/2017<\/td><td>5% 12%<\/td><\/tr><tr><td>30022011<\/td><td>Human Blood; Animal Blood Prepared For Therapeutic, Prophylactic Or Diagnostic Uses; Antisera And Other Blood Fractions And Modified Immunological Products, Whether Or Not Obtained By Means Of Biotechnological Processes; Vaccines, Toxins, Cultures Of Micr<\/td><td>5\/12<\/td><td>0<\/td><td>13\/10\/2017 1\/07\/2017<\/td><td>5% 12%<\/td><\/tr><tr><td>30022012<\/td><td>Human Blood; Animal Blood Prepared For Therapeutic, Prophylactic Or Diagnostic Uses; Antisera And Other Blood Fractions And Modified Immunological Products, Whether Or Not Obtained By Means Of Biotechnological Processes; Vaccines, Toxins, Cultures Of Micr<\/td><td>5\/12<\/td><td>0<\/td><td>13\/10\/2017 1\/07\/2017<\/td><td>5% 12%<\/td><\/tr><tr><td>30022013<\/td><td>Human Blood; Animal Blood Prepared For Therapeutic, Prophylactic Or Diagnostic Uses; Antisera And Other Blood Fractions And Modified Immunological Products, Whether Or Not Obtained By Means Of Biotechnological Processes; Vaccines, Toxins, Cultures Of Micr<\/td><td>5\/12<\/td><td>0<\/td><td>13\/10\/2017 1\/07\/2017<\/td><td>5% 12%<\/td><\/tr><tr><td>30022014<\/td><td>Human Blood; Animal Blood Prepared For Therapeutic, Prophylactic Or Diagnostic Uses; Antisera And Other Blood Fractions And Modified Immunological Products, Whether Or Not Obtained By Means Of Biotechnological Processes; Vaccines, Toxins, Cultures Of Micr<\/td><td>5\/12<\/td><td>0<\/td><td>13\/10\/2017 1\/07\/2017<\/td><td>5% 12%<\/td><\/tr><tr><td>30022015<\/td><td>Human Blood; Animal Blood Prepared For Therapeutic, Prophylactic Or Diagnostic Uses; Antisera And Other Blood Fractions And Modified Immunological Products, Whether Or Not Obtained By Means Of Biotechnological Processes; Vaccines, Toxins, Cultures Of Micr<\/td><td>5\/12<\/td><td>0<\/td><td>13\/10\/2017 1\/07\/2017<\/td><td>5% 12%<\/td><\/tr><tr><td>30022016<\/td><td>Human Blood; Animal Blood Prepared For Therapeutic, Prophylactic Or Diagnostic Uses; Antisera And Other Blood Fractions And Modified Immunological Products, Whether Or Not Obtained By Means Of Biotechnological Processes; Vaccines, Toxins, Cultures Of Micr<\/td><td>5\/12<\/td><td>0<\/td><td>13\/10\/2017 1\/07\/2017<\/td><td>5% 12%<\/td><\/tr><tr><td>30022017<\/td><td>Human Blood; Animal Blood Prepared For Therapeutic, Prophylactic Or Diagnostic Uses; Antisera And Other Blood Fractions And Modified Immunological Products, Whether Or Not Obtained By Means Of Biotechnological Processes; Vaccines, Toxins, Cultures Of Micr<\/td><td>5\/12<\/td><td>0<\/td><td>13\/10\/2017 1\/07\/2017<\/td><td>5% 12%<\/td><\/tr><tr><td>30022018<\/td><td>Human Blood; Animal Blood Prepared For Therapeutic, Prophylactic Or Diagnostic Uses; Antisera And Other Blood Fractions And Modified Immunological Products, Whether Or Not Obtained By Means Of Biotechnological Processes; Vaccines, Toxins, Cultures Of Micr<\/td><td>5\/12<\/td><td>0<\/td><td>13\/10\/2017 1\/07\/2017<\/td><td>5% 12%<\/td><\/tr><tr><td>30022019<\/td><td>Human Blood; Animal Blood Prepared For Therapeutic, Prophylactic Or Diagnostic Uses; Antisera And Other Blood Fractions And Modified Immunological Products, Whether Or Not Obtained By Means Of Biotechnological Processes; Vaccines, Toxins, Cultures Of Micr<\/td><td>5\/12<\/td><td>0<\/td><td>13\/10\/2017 1\/07\/2017<\/td><td>5% 12%<\/td><\/tr><tr><td>30022021<\/td><td>Human Blood; Animal Blood Prepared For Therapeutic, Prophylactic Or Diagnostic Uses; Antisera And Other Blood Fractions And Modified Immunological Products, Whether Or Not Obtained By Means Of Biotechnological Processes; Vaccines, Toxins, Cultures Of Micr<\/td><td>5\/12<\/td><td>0<\/td><td>13\/10\/2017 1\/07\/2017<\/td><td>5% 12%<\/td><\/tr><tr><td>30022022<\/td><td>Human Blood; Animal Blood Prepared For Therapeutic, Prophylactic Or Diagnostic Uses; Antisera And Other Blood Fractions And Modified Immunological Products, Whether Or Not Obtained By Means Of Biotechnological Processes; Vaccines, Toxins, Cultures Of Micr<\/td><td>5\/12<\/td><td>0<\/td><td>13\/10\/2017 1\/07\/2017<\/td><td>5% 12%<\/td><\/tr><tr><td>30022023<\/td><td>Human Blood; Animal Blood Prepared For Therapeutic, Prophylactic Or Diagnostic Uses; Antisera And Other Blood Fractions And Modified Immunological Products, Whether Or Not Obtained By Means Of Biotechnological Processes; Vaccines, Toxins, Cultures Of Micr<\/td><td>5\/12<\/td><td>0<\/td><td>13\/10\/2017 1\/07\/2017<\/td><td>5% 12%<\/td><\/tr><tr><td>30022024<\/td><td>Human Blood; Animal Blood Prepared For Therapeutic, Prophylactic Or Diagnostic Uses; Antisera And Other Blood Fractions And Modified Immunological Products, Whether Or Not Obtained By Means Of Biotechnological Processes; Vaccines, Toxins, Cultures Of Micr<\/td><td>5\/12<\/td><td>0<\/td><td>13\/10\/2017 1\/07\/2017<\/td><td>5% 12%<\/td><\/tr><tr><td>30022029<\/td><td>Human Blood; Animal Blood Prepared For Therapeutic, Prophylactic Or Diagnostic Uses; Antisera And Other Blood Fractions And Modified Immunological Products, Whether Or Not Obtained By Means Of Biotechnological Processes; Vaccines, Toxins, Cultures Of Micr<\/td><td>5\/12<\/td><td>0<\/td><td>13\/10\/2017 1\/07\/2017<\/td><td>5% 12%<\/td><\/tr><tr><td>30023000<\/td><td>Human Blood; Animal Blood Prepared For Therapeutic, Prophylactic Or Diagnostic Uses; Antisera And Other Blood Fractions And Modified Immunological Products, Whether Or Not Obtained By Means Of Biotechnological Processes; Vaccines, Toxins, Cultures Of Micr<\/td><td>5\/12<\/td><td>0<\/td><td>13\/10\/2017 1\/07\/2017<\/td><td>5% 12%<\/td><\/tr><tr><td>300290<\/td><td>Other<\/td><td>5\/12<\/td><td>0<\/td><td>13\/10\/2017 1\/07\/2017<\/td><td>5% 12%<\/td><\/tr><tr><td>30029010<\/td><td>Human Blood; Animal Blood Prepared For Therapeutic, Prophylactic Or Diagnostic Uses; Antisera And Other Blood Fractions And Modified Immunological Products, Whether Or Not Obtained By Means Of Biotechnological Processes; Vaccines, Toxins, Cultures Of Micr<\/td><td>5\/12<\/td><td>0<\/td><td>13\/10\/2017 1\/07\/2017<\/td><td>5% 12%<\/td><\/tr><tr><td>30029020<\/td><td>Human Blood; Animal Blood Prepared For Therapeutic, Prophylactic Or Diagnostic Uses; Antisera And Other Blood Fractions And Modified Immunological Products, Whether Or Not Obtained By Means Of Biotechnological Processes; Vaccines, Toxins, Cultures Of Micr<\/td><td>5\/12<\/td><td>0<\/td><td>13\/10\/2017 1\/07\/2017<\/td><td>5% 12%<\/td><\/tr><tr><td>30029030<\/td><td>Human Blood; Animal Blood Prepared For Therapeutic, Prophylactic Or Diagnostic Uses; Antisera And Other Blood Fractions And Modified Immunological Products, Whether Or Not Obtained By Means Of Biotechnological Processes; Vaccines, Toxins, Cultures Of Micr<\/td><td>5\/12<\/td><td>0<\/td><td>13\/10\/2017 1\/07\/2017<\/td><td>5% 12%<\/td><\/tr><tr><td>30029040<\/td><td>Human Blood; Animal Blood Prepared For Therapeutic, Prophylactic Or Diagnostic Uses; Antisera And Other Blood Fractions And Modified Immunological Products, Whether Or Not Obtained By Means Of Biotechnological Processes; Vaccines, Toxins, Cultures Of Micr<\/td><td>5\/12<\/td><td>0<\/td><td>13\/10\/2017 1\/07\/2017<\/td><td>5% 12%<\/td><\/tr><tr><td>30029090<\/td><td>Human Blood; Animal Blood Prepared For Therapeutic, Prophylactic Or Diagnostic Uses; Antisera And Other Blood Fractions And Modified Immunological Products, Whether Or Not Obtained By Means Of Biotechnological Processes; Vaccines, Toxins, Cultures Of Micr<\/td><td>5\/12<\/td><td>0<\/td><td>13\/10\/2017 1\/07\/2017<\/td><td>5% 12%<\/td><\/tr><\/tbody><\/table><\/figure>\n","protected":false},"excerpt":{"rendered":"<p>Origin Chapter:&nbsp;Chapter 30 Discover GST rates &amp; HSN code 3002 for Human and Animal Blood products. Ensure tax compliance with our comprehensive guide. HSN Code Description Rate (%) CESS (%) Effective Date Rate Revision 3002 Human Blood; Animal Blood Prepared For Therapeutic, Prophylactic Or Diagnostic Uses; Antisera, Other Blood Fractions And Immunological Products, Whether Or [&hellip;]<\/p>\n","protected":false},"author":4,"featured_media":70305,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","format":"standard","meta":[],"categories":[11190],"tags":[],"acf":{"service_id":"96"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v14.6.1 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Human Blood Animal Blood - GST Rates &amp; HSN Code 3002 - Enterslice<\/title>\n<meta name=\"description\" content=\"Discover GST rates &amp; HSN code 3002 for Human and Animal Blood products. Ensure tax compliance with our comprehensive guide.\" \/>\n<meta name=\"robots\" content=\"index, follow\" \/>\n<meta name=\"googlebot\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<meta name=\"bingbot\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/enterslice.com\/learning\/hsn-code\/3002\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Human Blood Animal Blood - GST Rates &amp; HSN Code 3002 - Enterslice\" \/>\n<meta property=\"og:description\" content=\"Discover GST rates &amp; HSN code 3002 for Human and Animal Blood products. Ensure tax compliance with our comprehensive guide.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/enterslice.com\/learning\/hsn-code\/3002\/\" \/>\n<meta property=\"og:site_name\" content=\"Enterslice\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/enterslice\" \/>\n<meta property=\"article:author\" content=\"enterslice\" \/>\n<meta property=\"article:modified_time\" content=\"2023-10-04T10:04:27+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary\" \/>\n<meta name=\"twitter:image\" content=\"https:\/\/enterslice.com\/learning\/wp-content\/uploads\/2023\/08\/GST-RATES-HSN-CODE-enterslice-blog-images-14-aug.webp\" \/>\n<meta name=\"twitter:creator\" content=\"@enterslice\" \/>\n<meta name=\"twitter:site\" content=\"@enterslice\" \/>\n<!-- \/ Yoast SEO plugin. -->","_links":{"self":[{"href":"https:\/\/enterslice.com\/learning\/wp-json\/wp\/v2\/hsn-code\/72632"}],"collection":[{"href":"https:\/\/enterslice.com\/learning\/wp-json\/wp\/v2\/hsn-code"}],"about":[{"href":"https:\/\/enterslice.com\/learning\/wp-json\/wp\/v2\/types\/hsn-code"}],"author":[{"embeddable":true,"href":"https:\/\/enterslice.com\/learning\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/enterslice.com\/learning\/wp-json\/wp\/v2\/comments?post=72632"}],"version-history":[{"count":2,"href":"https:\/\/enterslice.com\/learning\/wp-json\/wp\/v2\/hsn-code\/72632\/revisions"}],"predecessor-version":[{"id":72634,"href":"https:\/\/enterslice.com\/learning\/wp-json\/wp\/v2\/hsn-code\/72632\/revisions\/72634"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/enterslice.com\/learning\/wp-json\/wp\/v2\/media\/70305"}],"wp:attachment":[{"href":"https:\/\/enterslice.com\/learning\/wp-json\/wp\/v2\/media?parent=72632"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/enterslice.com\/learning\/wp-json\/wp\/v2\/categories?post=72632"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/enterslice.com\/learning\/wp-json\/wp\/v2\/tags?post=72632"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}